Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-01-13
2002-04-30
Ford, John M. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S284000, C544S290000
Reexamination Certificate
active
06380204
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention relates to atropisomers of 3-heteroaryl-4(3H)-quinazolinones of the formula Ia, described below, and their pharmaceutically acceptable salts, and pharmaceutical compositions and methods of treating neurodegenerative and CNS-trauma related conditions.
Atropisomers are isomeric compounds that are chiral, i.e. each isomer is not superimposable on its mirror image and the isomers, once separated, rotate polarized light in equal amounts but opposite directions. Atropisomers are distinguished from enantiomers in that atropisomers do not possess a single asymmetric atom. Atropisomers are conformational isomers which occur when rotation about a single bond in the molecule is prevented or greatly slowed as a result of steric interactions with other parts of the molecule and the substituents at both ends of the single bond are unsymmetrical. A detailed account of atropisomers can be found in Jerry March,
Advanced Organic Chemistry
, 101-102 (4th ed. 1992) and in Oki,
Top. Stereochem
., 14, 1-81 (1983).
The compounds of the invention provide the first evidence that atropisomers of quinazolinones are separable and that the separated isomers possess differential AMPA receptor antagonist activity. (AMPA receptors are a subspecies of glutamate receptors, identified by their ability to bind &agr;-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), that are post-synaptic neurotransmitter receptors for excitatory amino acids.) Colebrook et al.,
Can. J. Chem
., 53, 3431-4, (1975) observed hindered rotation about aryl C═N bonds in quinazolinones but did not separate or suggest that the rotational isomers could be separated. U.S. patent application Ser. No. 60/017,738 filed May 15,1996 and entitled “Novel 2,3-Disubstituted-4-(3H)-Quinazolinones” and U.S. patent application Ser. No. 60/017,737 filed May 15, 1996 and entitled “Novel 2,3-Disubstituted-(5,6)-Heteroarylfused-Pyrimidin-4-ones,” both applications herein incorporated by reference in there entirety, refer to racemic quinazolinones and pyrimidinones. Suprisingly, the inventors of the present invention have discovered that one quinazolinone isomer, defined by the spatial positions of the substituents arising out of steric interactions, possesses all of the AMPA receptor antagonist activity.
The role of excitatory amino acids, such as glutamic acid and aspartic acid, as the predominant mediators of excitatory synaptic transmission in the central nervous system has been well established. Watkins & Evans,
Ann. Rev. Pharmacol. Toxicol
., 21, 165 (1981); Monaghan, Bridges,and Cotman,
Ann. Rev. Pharmacol. Toxicol
., 29, 365 (1989); Watkins, Krogsgaard-Larsen, and Honore,
Trans. Pharm. Sci
., 11, 25 (1990). These amino acids function in synaptic transmission primarily through excitatory amino acid receptors. These amino acids also participate in a variety of other physiological processes such as motor control, respiration, cardiovascular regulation, sensory perception, and cognition.
Excitatory amino acid receptors are classified into two general types. Receptors that are directly coupled to the opening of cation channels in the cell membrane of the neurons are termed “ionotropic.” This type of receptor has been subdivided into at least three subtypes, which are defined by the depolarizing actions of the selective agonists N-methyl-D-aspartate (NMDA), &agr;-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), and kainic acid (KA). The second general type is the G-protein or second messenger-linked “metabotropic” excitatory amino acid receptor. This second type, when activated by the agonists quisqualate, ibotenate, or trans-1-aminocyclopentane-1,3-dicarboxylic acid, leads to enhanced phosphoinosoitide hydrolysis in the postsynaptic cell. Both types of receptors appear not only to mediate normal synaptic transmission along excitatory pathways, but also participate in the modification of synaptic connection during development and changes in the efficiency of synaptic transmission throughout life. Schoepp, Bockaert, and Sladeczek.
Trends in Pharmacol. Sci
., 11, 508 (1990); McDonald and Johnson,
Brain Research Reviews
, 15, 41 (1990).
The excessive or inappropriate stimulation of excitatory amino acid receptors leads to neuronal cell damage or loss by way of a mechanism known as excitotoxicity. This process has been suggested to mediate neuronal degeneration in a variety of conditions. The medical consequences of such neuronal degeneration makes the abatement of these degenerative neurological processes an important therapeutic goal.
Excitatory amino acid excitotoxicity has been implicated in the pathophysiology of a number of neurological disorders. This excitotoxicity has been implicated in the pathophysiology of acute and chronic neurodegenerative conditions including cerebral deficits subsequent to cardiac bypass surgery and grafting, stroke, cerebral ischemia, spinal cord trauma, head trauma, Alzheimer's Disease, Huntington's Chorea, amyotrophic lateral sclerosis, epilepsy, AIDS-induced dementia, perinatal hypoxia, hypoxia (such as conditions caused by strangulation, surgery, smoke inhalation, asphyxiation, drowning, choking, electrocution or drug or alcohol overdose), cardiac arrest, hypoglycemic neuronal damage, ocular damage and retinopathy, and idiopathic and drug-induced Parkinson's Disease. Other neurological conditions, that are caused by glutamate dysfunction, require neuromodulation. These other neurological conditions include muscular spasms, migraine headaches, urinary incontinence, psychosis, addiction withdrawal (such as alcoholism and drug addiction including opiate, cocaine and nicotine addiction), opiate tolerance, anxiety, emesis, brain edema, chronic pain, convulsions, retinal neuropathy, tinnitus and tardive dyskinesia. The use of a neuroprotective agent, such as an AMPA receptor antagonist, is believed to be useful in treating these disorders and/or reducing the amount of neurological damage associated with these disorders. The excitatory amino acid receptor (EAA) antagonists are also useful as analgesic agents.
Several studies have shown that AMPA receptor antagonists are neuroprotective in focal and global ischemia models. The competitive AMPA receptor antagonist NBQX (2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f-]quinoxaline) has been reported effective in preventing global and focal ischemic damage. Sheardown et al.,
Science
, 247, 571 (1900); Buchan et al.,
Neuroreport
, 2, 473 (1991); LePeillet et al.,
Brain Research
, 571, 115 (1992). The noncompetitive AMPA receptor antagonists GKYI 52466 has been shown to be an effective neuroprotective agent in rat global ischemia models. LaPeillet et al.,
Brain Research
, 571, 115 (1992). These studies strongly suggest that the delayed neuronal degeneration in brain ischemia involves glutamate excitotoxicity mediated at least in part by AMPA receptor activation. Thus, AMPA receptor antagonists may prove useful as neuroprotective agents and improve the neurological outcome of cerebral ischemia in humans.
SUMMARY OF THE INVENTION
The present invention relates to an atropisomer of the formula
wherein each of “A, B and D” is nitrogen or —CH—, with the proviso that only one of “A”, “B” and “D” can be nitrogen; wherein n is an integer from one to four, preferably one to or two, and wherein each R
5
is a substituent on any carbon atom of the “A, B, D” ring capable of supporting an additional bond, with the proviso that one R
5
must be attached to a carbon atom ortho to the asterisked carbon of the ring; wherein each R
5
may be independently selected from the group consisting of (C
1
-C
6
)alkyl, halogen, trifluoromethyl, amino-(CH
2
)
m
—, (C
1
-C
6
)alkylamino-(CH
2
)
m
—, di(C
1
-C
6
)alkyl-amino-(CH
2
)
m
—, (C
1
-C
6
)alkoxy, hydroxy(C
1
-C
6
)alkyl-, (C
1
-C
6
)alkyl-O—(C
1
-C
6
)alkyl-, —CN, hydroxy-(CH
2
)
m
—, (C
1
-C
6
)alkyl-(O═C)—O—(C
1
-C
6
)alkyl-, (C
1
-C
6
)alkyl-O—(C═O)—O—(C
1
-C
6
)alkyl, (C
1
-C
6
)alkyl-(O═C)—O—, H—(C═O)—(CH
2
)
m
—, (C
1
-C
6
)al
Chenard Bertrand Leo
Devries Keith Michael
Welch, Jr. Willard McKowan
Ford John M.
Ginsburg Paul H.
Joran A. David
Pfizer INC
Richardson Peter C.
LandOfFree
Atropisomers of 3-heteroaryl-4(3H)-quinazolinones for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Atropisomers of 3-heteroaryl-4(3H)-quinazolinones for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Atropisomers of 3-heteroaryl-4(3H)-quinazolinones for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2896921